S-(-)-2-hydroxy-3-methoxy-(2',2'-difluoro-10,11-methylenedioxy)-5,8,13,13a-tetrahydro-6H-dibenzo[a,g]quinolizine | 1415465-51-8

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 原小檗碱生物碱及其衍生物
• 英文名称: S-(-)-2-hydroxy-3-methoxy-(2',2'-difluoro-10,11-methylenedioxy)-5,8,13,13a-tetrahydro-6H-dibenzo[a,g]quinolizine
• 英文别名: DC037037；(13S)-7,7-difluoro-17-methoxy-6,8-dioxa-1-azapentacyclo[11.8.0.03,11.05,9.014,19]henicosa-3,5(9),10,14,16,18-hexaen-16-ol
• CAS: 1415465-51-8
• 化学式: C₁₉H₁₇F₂NO₄
• 分子量: 361.345
• InChiKey: QCXCNKGMHYODSS-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  26
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：US20140088130A1

  公开（公告）日：2014-03-27

  The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on.

  本发明涉及一种由通式（I）表示的新型六氢二苯并[a,g]喹啉化合物及其衍生物、对映体、非对映体异构体、混合物以及其药学上可接受的盐。本发明还涉及一种制备该化合物的方法，该化合物对神经系统疾病具有良好的预防和治疗效果，特别是与多巴胺受体和5-羟色胺受体相关的疾病。生物活性实验证明，该化合物有望被开发成一种新型和有效的化学实体，用于治疗与多巴胺受体和5-羟色胺受体相关的疾病，特别是精神分裂症、帕金森病、药物成瘾、偏头痛等疾病。
• US9359372B2
  申请人：——

  公开号：US9359372B2

  公开（公告）日：2016-06-07